DxM MicroScan WalkAway System
Detect antimicrobial resistance with proven expertise
Receive your quote directly from the manufacturer.
Detect antimicrobial resistance with proven expertise
The DxM MicroScan WalkAway system delivers trusted detection of emerging and critical antimicrobial resistance with gold-standard MIC accuracy. Designed with ease of use as a focal point, this bacterial identification and antimicrobial susceptibility testing (ID/AST) system provides streamlined workflows and enhanced performance compared to its predecessors. The DxM MicroScan WalkAway system continues the legacy of innovation and high-quality products you have trusted for 40 years. Enable your laboratory to optimize patient care while reducing risks, costs and operational burden associated with detecting emerging antimicrobial resistance.
Brochures
Your laboratory's pathway to accurate antibiotic prescription
Antibiotic resistance is one of the greatest threats to global public health—projected to cause 10 million deaths annually by 2050. The ability to prescribe the right antibiotic at the right time has never been more critical.
In this brochure, find out how Beckman Coulter’s DxM Trio delivers the precision and speed your clinical laboratory needs to support effective antibiotic stewardship.
Key takeaways
- Real-time detection
Detect emerging resistance confidently with MicroScan® panels—ensuring accurate and timely results. - Rapid organism ID
Identify pathogens in minutes using Bruker’s MALDI Biotyper® sirius System—the most comprehensive organism library on the market. - Direct ID from positive blood cultures
Save time and improve outcomes with Bruker’s MBT Sepsityper® for faster turnaround. - Workflow efficiency
Intuitive interface and visual cues on the DxM MicroScan WalkAway system help streamline lab operations.
With antibiotic development slowing and resistance accelerating, your laboratory plays a pivotal role. Download the brochure to learn how to empower your team to identify threats early, guide appropriate therapy, and optimize care—safely, efficiently, and reliably.
Suspect, diagnose, and confirm sepsis
In this brochure, Beckman Coulter describes the steps involved in diagnosing sepsis and the points where its technology can be utilized to assist in the process. Without timely treatment, sepsis can rapidly progress to tissue damage, organ failure, and death. Upon suspicion of sepsis, blood samples can be analyzed with the DxH 900 Analyzer and urine samples with the DxU Iris Analyzer. Further testing can then be performed with the DxC700 AU Analyzer and the Dxl 9000 Access Immunoassay Analyzer. Finally, for confirmation, the pathogen can be identified with the DxM MicroScan WalkAway ID/AST System.
Improving diagnosis of sepsis with early recognition of AMR
Post-pandemic, hospital-onset infections from resistant pathogens have surged, with significant increases in carbapenem-resistant, ESßL-producing, and multidrug-resistant infections. Antimicrobial resistance (AMR) and its impact on sepsis, a condition affecting 49 million people and causing 11 million deaths annually, urgently needs to be addressed. Download this resource to discover how Beckman Coulter’s MicroScan systems provide accurate, timely resistance detection, supporting better antimicrobial therapy decisions to combat this costly and deadly condition.
Pathway to prescription: The Beckman Coulter DxM Trio
In this application note, Beckman Coulter provides information on the DxM Trio system, designed to support antibiotic stewardship initiatives, and provide faster patient results. The DxM Trio brings the accuracy of the DxM MicroScan WalkAway system, the speed of the mass spectrometry with the Bruker MALDI Biotyper® system, and the efficiency of LabPro-MBT software.
The key highlights of this system includes:
- Rapid ID generation within minutes with the largest organism library on the market using MALDI-TOF technology
- Cybersecurity threat protection with heightened security features across the platform from LabPro v5.0 and Windows 10
- Seamless ID integration with AST results with sophisticated middleware using LabPro-MBT or HighFlexX v2.9
The pathway to prescription for sepsis patients
This infographic describes the pathway to prescription for sepsis patients. Learn how Beckman Coulter’s MicroScan platform can be used to confirm whether an Extended Spectrum Beta-Lactamase (ESBL)-producing organism is causing the infection, enabling physicians to prescribe the most effective treatment to the patient.
Resistance on the rise
Join Dr. Ahmed Babiker, Assistant Professor, Rush University, and Professor Elaine Cloutman-Green, Principal Clinical Scientist in Infection Control at Great Ormond Street Hospital for Children, London as they explore the evolution of superbugs and superbugs’ impact to clinical treatment. They will present case study examples, and discuss global infection prevention strategies to support antibiotic stewardship.
Key learning objectives
- Explore the evolution of superbugs and current top priority global threats
- Recognize the impact, and outcome, of resistant bacteria present in the clinical setting
- Explore key infection prevention strategies
Who should attend?
- Clinical microbiology lab directors/supervisors/managers
- Microbiologists
- Microbiologist lab technicians
- Infectious disease specialists
- Infectious disease pharmacists
- Clinical microbiology lab executives
- Antibiotic stewardship committee members
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Managing antimicrobial resistance: A healthcare system's approach to antimicrobial detection and stewardship
Over the past five years, healthcare systems have faced a troubling rise in Gram-negative multidrug-resistant organisms (MDROs), contributing to increased patient morbidity and mortality. At the forefront of this surge are NDM-CREs (New Delhi metallo-β-lactamase-producing carbapenem-resistant Enterobacterales), which have skyrocketed by 460% between 2019 and 2023, according to a recent report from the Centers for Disease Control and Prevention (CDC)1. Another report by the European Centre for Disease Control (ECDC) showed a 57% increase in bloodstream infections caused by carbapenem resistant bacteria in the same time period2.
These alarming trends underscore the urgent need for robust screening protocols and precise antibiotic susceptibility testing, especially for high-risk patient populations.
Join our group of industry experts for an insightful case-based webinar exploring the complex patient journey of a 76-year-old woman residing in a nursing home. Her story begins with a fall leading to an emergency room visit where she is found to have a hip fracture. She is admitted and has an uneventful surgical repair the next day but develops urosepsis during her post-op recovery.
This case highlights the heightened vulnerability of elderly patients to MDROs, particularly CREs. Through this patient’s journey, the speakers will examine the critical role of infection prevention protocols and the value of accurate diagnostic and antibiotic susceptibility testing in guiding effective treatment as they are applied throughout a healthcare system.
The session will also incorporate the latest IDSA guidelines for managing complicated urinary tract infections, including urosepsis, offering practical insights for clinicians, microbiologists, and infection control professionals.
Key learning objectives:
- Describe how rapid PCR screening plays a critical role in enhancing infection control protocols to help minimize transmission and support timely patient management.
- Explain how rapid AST results support optimal antimicrobial therapy decision-making to help improve patient outcomes and combat resistance.
- Outline the latest IDSA guidelines for complicated urinary tract infections.
- Discuss the impact of antimicrobial resistance and diagnostic stewardship in real-world settings.
Who should attend?
Clinical microbiology lab directors/supervisors/managers, microbiologists, microbiologist lab technicians, infectious disease specialists, infectious disease pharmacists, clinical microbiology lab executives, antibiotic stewardship committee members, infection preventionists
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
References:
1. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria | CDC Newsroom
2. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2023
MIC vs. Resistance mechanisms: What is needed to treat MDRO gram negative infections?
Phenotypic antimicrobial susceptibility testing is the gold standard test for treatment decisions, but emerging antimicrobial resistance and new antimicrobials for Gram-negative bacterial infections are challenging the conventional wisdom that a minimum inhibitory concentration (MIC) is all that is needed. Asking the question, "How can we meet evolving diagnostic needs?", we hear from three key microbiology and infectious disease experts: Prof. Navaneeth Narayanan, Rutgers University Ernest Mario School of Pharmacy, Prof. Amy Mathers, University of Virginia, School of Medicine, and Dr. April Abbott, Deaconess Health System, in this educational webinar.
Key learning objectives
- Discover the new drugs available for treating MDRO Gram-negative infections
- Understand the challenges and opportunities associated with MDRO Gram-negative diagnostics
Who should attend?
- Clinical microbiology lab directors/supervisors/managers
- Microbiologists
- Microbiologist lab technicians
- Infectious disease specialists
- Infectious disease pharmacists
- Clinical microbiology lab executives
- Antibiotic stewardship committee members
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Beckman Coulter Diagnostics improves patient care with synergistic immunoassay and microbiology solutions
Beckman Coulter Immunoassay and Beckman Coulter Microbiology have joined forces at ESCMID Global to introduce the DxI 9000 Immunoassay Analyzer where the company launched a brand-new suite of blood virus assays to the public. This new suite of assays complements the Microbiology portfolio to provide mechanisms for early detection and confirmation of bacterial and viral infections to improve patient outcomes. Discover how Beckman Coulter Diagnostics is transforming the landscape of diagnostic testing, offering a patient-centric approach with unprecedented accuracy, efficiency, and reliability.
This video was filmed at ESCMID Global 2024.
Advanced clinical microbiology diagnostics for combatting antimicrobial resistance
In this video, Rachael Arkley and Michael Dawson from William Harvey Hospital highlight the latest clinical laboratory trends and how the DxM MicroScan WalkAway system from Beckman Coulter has helped them enhance laboratory efficiency and elevate their clinical diagnostic services. By utilizing the LabPro database, the DxM MicroScan provides expert-level antimicrobial interpretation and results. Therefore improving quality control, minimizing the need to retest patient specimens, and ultimately aiding in the combat against antimicrobial resistance.
This video was filmed at ECCMID 2023, Copenhagen
Combating antimicrobial resistance: Detection is key
Antimicrobial resistance poses a profound threat to human health. To combat antimicrobial resistance, accurate detection is critical. In this video, Beckman Coulter introduces its DxM MicroScan WalkAway system, designed to bring gold-standard, accurate detection to your lab.
Beckman Coulter MicroScan wins IMV ServiceTrak Best System Performance at AACC
The MicroScan WalkAway family of instruments was presented with the award for the second year in a row
